Protara Therapeutics ROA 2024

Protara Therapeutics Aktienanalyse

What does Protara Therapeutics do?

Protara Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for rare and severe immune system disorders. It was founded in 2012 and is based in Tarrytown, New York. The company was formed through the merger of NeuroproteXeon, Inc. and Biokine Therapeutics Ltd, with the goal of developing a pipeline of novel therapeutics for rare immune system diseases. In 2018, the company was acquired by Protea Biosciences Group Inc. Protara's business model revolves around the discovery, development, and commercialization of innovative therapeutics for immune system disorders. The company utilizes various technologies and platforms, including its proprietary protein engine, to drive its innovation program. It currently has two main divisions: one focused on the development and commercialization of T-cell-engaging Bi-Specifics, a novel class of immunotherapeutics specialized in tumor antigen-specific T-cell activation, and another division offering innovative nanotechnology platforms for the development of drugs for the treatment of inflammatory and immune disorders. Protara's leading pipeline products include TULIP Bi-Specific (JNJ-63898081), a T-cell-engaging Bi-Specific against CD3 and BCMA in phase I/IIa clinical trials for patients with multiple myeloma, and RTX-240, a T-cell-engaging Bi-Specific against CD3 and PSMA in the development phase for patients with advanced solid tumors. The company also focuses on developing precursor molecules for T-cell-engaging Bi-Specifics and protein engineering and optimization technologies to enhance the effectiveness and half-life of immunotherapeutics. Additionally, Protara has proprietary nanoparticle platforms, known as NANOMAbs, with promising applications in the treatment of inflammatory and immune disorders such as COVID-19, lupus, dermal diseases, and others. In summary, Protara Therapeutics Inc is a leading biopharmaceutical company focused on innovative therapies for immune system disorders. Its pipeline includes T-cell-engaging Bi-Specifics and proprietary nanoparticle platforms with promising applications in the treatment of inflammatory and immune disorders. With its complex technology and protein development and optimization capabilities, Protara continues to create groundbreaking new treatment options for patients. Protara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Protara Therapeutics's Return on Assets (ROA)

Protara Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Protara Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Protara Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Protara Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Protara Therapeutics Stock

What is the Return on Assets (ROA) of Protara Therapeutics this year?

The Return on Assets (ROA) of Protara Therapeutics is -0.51 undefined this year.

What was the ROA of Protara Therapeutics compared to the previous year?

The ROA of Protara Therapeutics has increased by -12.05% compared to the previous year.

What consequences do high ROA have for investors of Protara Therapeutics?

A high ROA is advantageous for investors of Protara Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Protara Therapeutics?

A low ROA can be unfavorable for investors of Protara Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Protara Therapeutics affect the company?

An increase in ROA of Protara Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Protara Therapeutics impact the company?

A reduction in the ROA of Protara Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Protara Therapeutics?

Some factors that can influence the ROA of Protara Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Protara Therapeutics important for investors?

The ROA of Protara Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Protara Therapeutics take to improve ROA?

To improve ROA, Protara Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Protara Therapeutics pay?

Over the past 12 months, Protara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Protara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Protara Therapeutics?

The current dividend yield of Protara Therapeutics is .

When does Protara Therapeutics pay dividends?

Protara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Protara Therapeutics?

Protara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Protara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Protara Therapeutics located?

Protara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Protara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Protara Therapeutics from 7/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/3/2024.

When did Protara Therapeutics pay the last dividend?

The last dividend was paid out on 7/3/2024.

What was the dividend of Protara Therapeutics in the year 2023?

In the year 2023, Protara Therapeutics distributed 0 USD as dividends.

In which currency does Protara Therapeutics pay out the dividend?

The dividends of Protara Therapeutics are distributed in USD.